Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinoma
Open Access
- 17 May 2024
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (28) , 1-11
Abstract
The standard preoperative treatment for resectable locally advanced esophageal squamous cell carcinoma (ESCC) is chemoradiotherapy in western countries (based on the CROSS trial) and triplet chemotherapy in Japan (based on the JCOG1109 trial). Postoperative nivolumab has recently been shown to improve disease-free survival in resectable locally advanced esophageal cancer after preoperative chemoradiotherapy in patients who had residual pathological disease, based on the CheckMate 577 trial. Furthermore, preoperative immune checkpoint inhibitor-containing treatments have also been developed. The JCOG1804E trial is presently evaluating the safety and efficacy of preoperative nivolumab-containing chemotherapy for resectable locally advanced ESCC. This review discusses the treatment of resectable locally advanced ESCC and future perspectives on perioperative immune checkpoint inhibitor-containing treatments.Keywords
This publication has 79 references indexed in Scilit:
- Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2Esophagus, 2023
- Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1Esophagus, 2023
- Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatinEsophagus, 2022
- Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC‐ESCC2019): A multicenter, phase 2 studyInternational Journal of Cancer, 2022
- Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II studyESMO Open, 2022
- Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaJAMA Surgery, 2021
- Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)European Journal of Cancer, 2021
- The Link Between the Gut Microbiome and Response to Immune Checkpoint Inhibitors in Renal Cell CarcinomaEuropean Urology, 2021
- Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival—The University of Texas MD Anderson Cancer Center experienceCancer, 2017
- Esophageal Carcinoma: Prognostic Differences between Squamous Cell Carcinoma And AdenocarcinomaWorld Journal of Surgery, 2004